Breast Cancer Clinical Trials & Research at Providence Medical Group

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

Providence Medical Group is currently enrolling patients for the following breast cancer clinical trials:

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (MA.39 TAILOR RT)

Treatment agent: Radiotherapy
Physician: Michael N. Corradetti, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / Canadian Cancer Trials Group
Location: Providence Queen of the Valley Medical Center, Napa, CA

Sermonix SMX-22-002 ELAINE 3

Treatment agent: Lasofoxifene + abemaciclib vs fulvestrant + abemaciclib
Physician: Jarrod Holmes, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation - Full Text View - ClinicalTrials.gov
Sponsor: Sermonix Pharmaceuticals Inc.
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with ER/PR+, HER2- locally recurrent or metastatic breast cancer: AZ D8534C00001

Treatment agent: AZD9833 (oral medication) + CDK4/6 inhibitor
Physician: Jarrod Holmes, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with unresectable and/or metastatic breast cancer who have newly initiated T-DXd (Enhertu) (DB RESPOND)

Treatment agent: Observational study
Physician: Jarrod Holmes, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

Treatment agent: Magrolimab, nab-paclitaxel, and paclitaxel
Physician: Jarrod Holmes, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer - Full Text View - ClinicalTrials.gov
Sponsor: Gilead Sciences
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with previously intreated locally advanced inoperable or metastatic triple negative breast cancer (ASCENT-04)

Treatment agent: Sacituzimab govitecan + pembrolizumab
Physician: Jarrod Holmes, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer - Full Text View - ClinicalTrials.gov
Sponsor: Gilead Sciences
Location: Providence Cancer Center Santa Rosa, CA

A study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

Treatment agent: ARV-471 vs Fulvestrant
Physician: Gurinder Sidhu, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT05654623
Sponsor: Pfizer
Location: Providence Queen of the Valley Medical Center, Napa, CA

A study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

Treatment agent: ARV-471 vs Fulvestrant
Physician: Jarrod Holmes, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT05654623
Sponsor: Pfizer
Location: Providence Cancer Center Santa Rosa, CA